Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Fonar Corporation stock logo
FONR
Fonar
$15.46
-0.8%
$13.98
$12.00
$18.68
$95.85M117,369 shs12,596 shs
InspireMD, Inc. stock logo
NSPR
InspireMD
$2.43
+7.5%
$2.43
$1.99
$3.80
$74.44M0.5768,361 shs281,700 shs
Nexalin Technology, Inc. stock logo
NXL
Nexalin Technology
$0.99
+2.9%
$1.20
$0.59
$4.49
$17.01M3.7579,541 shs60,328 shs
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
$4.59
-0.4%
$4.70
$4.01
$9.33
$75.46M1.29190,100 shs44,031 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Fonar Corporation stock logo
FONR
Fonar
+0.84%-0.19%+7.67%+24.12%-2.93%
InspireMD, Inc. stock logo
NSPR
InspireMD
+1.80%+1.35%-9.60%-13.08%-6.22%
Nexalin Technology, Inc. stock logo
NXL
Nexalin Technology
+1.26%-2.83%-25.43%-45.65%-35.00%
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
+0.44%-0.65%-6.30%+0.44%-18.69%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Fonar Corporation stock logo
FONR
Fonar
1.25 of 5 stars
0.03.00.00.01.80.81.9
InspireMD, Inc. stock logo
NSPR
InspireMD
3.4982 of 5 stars
3.54.00.00.03.32.50.6
Nexalin Technology, Inc. stock logo
NXL
Nexalin Technology
2.3127 of 5 stars
3.53.00.00.02.11.70.0
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
1.492 of 5 stars
3.63.00.00.00.60.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Fonar Corporation stock logo
FONR
Fonar
0.00
N/AN/AN/A
InspireMD, Inc. stock logo
NSPR
InspireMD
3.00
Buy$4.5085.19% Upside
Nexalin Technology, Inc. stock logo
NXL
Nexalin Technology
3.00
Buy$5.00405.05% Upside
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
3.25
Buy$11.67154.18% Upside

Current Analyst Ratings Breakdown

Latest NXL, FONR, NSPR, and SRTS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/19/2025
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$14.00 ➝ $10.00
5/12/2025
InspireMD, Inc. stock logo
NSPR
InspireMD
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$4.50 ➝ $4.00
(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Fonar Corporation stock logo
FONR
Fonar
$102.88M0.93$3.08 per share5.02$24.78 per share0.62
InspireMD, Inc. stock logo
NSPR
InspireMD
$7.03M10.59N/AN/A$1.83 per share1.33
Nexalin Technology, Inc. stock logo
NXL
Nexalin Technology
$170K100.05N/AN/A$0.28 per share3.54
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
$41.81M1.80$0.43 per share10.63$3.41 per share1.35
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Fonar Corporation stock logo
FONR
Fonar
$10.57M$1.2512.37N/A8.19%5.31%3.97%9/25/2025 (Estimated)
InspireMD, Inc. stock logo
NSPR
InspireMD
-$19.92M-$0.79N/AN/AN/A-413.96%-69.42%-57.68%N/A
Nexalin Technology, Inc. stock logo
NXL
Nexalin Technology
-$7.61M-$0.83N/AN/A-6,529.77%-277.92%-245.37%8/14/2025 (Estimated)
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
$6.65M$0.1045.9019.96N/A4.56%3.34%3.00%8/6/2025 (Estimated)

Latest NXL, FONR, NSPR, and SRTS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q3 2025
Fonar Corporation stock logo
FONR
Fonar
N/A$0.37N/A$0.37N/AN/A
5/15/2025Q1 2025
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
$0.04-$0.16-$0.20-$0.16$7.23 million$8.34 million
5/13/2025Q1 2025
Nexalin Technology, Inc. stock logo
NXL
Nexalin Technology
-$0.10-$0.15-$0.05-$0.15$0.04 million$0.04 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Fonar Corporation stock logo
FONR
Fonar
N/AN/AN/AN/AN/A
InspireMD, Inc. stock logo
NSPR
InspireMD
N/AN/AN/AN/AN/A
Nexalin Technology, Inc. stock logo
NXL
Nexalin Technology
N/AN/AN/AN/AN/A
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Fonar Corporation stock logo
FONR
Fonar
N/A
10.05
9.86
InspireMD, Inc. stock logo
NSPR
InspireMD
N/A
6.39
6.05
Nexalin Technology, Inc. stock logo
NXL
Nexalin Technology
N/A
4.56
4.25
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
N/A
8.06
5.74

Institutional Ownership

CompanyInstitutional Ownership
Fonar Corporation stock logo
FONR
Fonar
50.64%
InspireMD, Inc. stock logo
NSPR
InspireMD
44.78%
Nexalin Technology, Inc. stock logo
NXL
Nexalin Technology
0.65%
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
25.30%

Insider Ownership

CompanyInsider Ownership
Fonar Corporation stock logo
FONR
Fonar
1.55%
InspireMD, Inc. stock logo
NSPR
InspireMD
34.06%
Nexalin Technology, Inc. stock logo
NXL
Nexalin Technology
25.26%
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
8.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Fonar Corporation stock logo
FONR
Fonar
4806.20 million6.11 millionNot Optionable
InspireMD, Inc. stock logo
NSPR
InspireMD
5030.64 million18.33 millionOptionable
Nexalin Technology, Inc. stock logo
NXL
Nexalin Technology
317.18 million12.84 millionNot Optionable
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
4016.44 million14.98 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Fonar stock logo

Fonar NASDAQ:FONR

$15.46 -0.13 (-0.83%)
Closing price 04:00 PM Eastern
Extended Trading
$16.50 +1.05 (+6.76%)
As of 06:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

FONAR Corporation, together with its subsidiaries, engages in the research, development, production, and marketing of magnetic resonance imaging (MRI) scanners for the detection and diagnosis of human diseases in the United States. The company operates in two segments, Medical Equipment, and Physician Management and Diagnostic Services. It provides Upright MRI scanner that allows patients to be scanned in weight-bearing conditions, such as standing, sitting, bending, or lying down. The company also offers non-medical management, including administrative services, billing and collection services, credentialing services, contract negotiations, compliance consulting, purchasing IT services, hiring, conducting interviews, training, supervision and management of non-medical personnel, storage of medical records, office space, equipment, repair maintenance services, accounting, assistance with compliance matters, and development and implementation of practice growth and marketing strategies. It owns and operates diagnostic imaging facilities in Florida; and manages MRI scanning facilities. The company markets its scanners to private diagnostic imaging centers and hospital outpatient imaging facilities. FONAR Corporation was founded in 1970 and is based in Melville, New York.

InspireMD stock logo

InspireMD NYSE:NSPR

$2.43 +0.17 (+7.52%)
Closing price 04:00 PM Eastern
Extended Trading
$2.36 -0.07 (-2.72%)
As of 06:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.

Nexalin Technology stock logo

Nexalin Technology NASDAQ:NXL

$0.99 +0.03 (+2.91%)
Closing price 04:00 PM Eastern
Extended Trading
$1.01 +0.02 (+1.82%)
As of 05:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The company is based in Houston, Texas.

Sensus Healthcare stock logo

Sensus Healthcare NASDAQ:SRTS

$4.59 -0.02 (-0.43%)
Closing price 04:00 PM Eastern
Extended Trading
$4.76 +0.17 (+3.70%)
As of 06:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sensus Healthcare, Inc., a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides SRT-100 Plus; Sentinel service program, which offers its customers protection for their systems; and Transdermal Infusion system, a biophysical alternative to infuse high weight molecule modalities into the dermis for medical and aesthetic purposes without the use of needles. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons and eye shields, ultrasound probe film, and disposable applicator tips to treat various sized lesions and various areas of the body. Further, the company distributes laser devices, which includes applications for hair removal, vascular lesions, acne treatment, skin toning, and skin rejuvenation, as well as epidermal pigment removal for spots, freckles, and tattoos. It markets its products primarily to private dermatology practices, and radiation oncologists in both private and hospital settings. Sensus Healthcare, Inc. was incorporated in 2010 and is headquartered in Boca Raton, Florida.